Literature DB >> 10713330

STAT6 and the regulation of CD23 expression in B-chronic lymphocytic leukemia.

C Kneitz1, M Goller, R Seggewiss, A Yaman, E Serfling, H P Tony.   

Abstract

High CD23 expression is a hallmark of B-CLL cells. It is lost during in vitro culture and can be reinduced by IL-4, albeit to a lower extent than in normal B cells. To elucidate the events controlling CD23 expression in B-CLL cells, the IL-4 mediated induction of STAT6 was investigated. Western-blot analysis demonstrated that B-CLL cells contain comparable amounts of STAT6. Electrophoretic mobility shift assays (EMSA) showed no constitutive nuclear translocation of STAT6. IL-4 induced the translocation of STAT6 in B-CLL cells from all 22 patients investigated. The increase was transient, dose and time dependent without a distinct difference between B-CLL cells and non-malignant B cells. However, in contrast to normal B lymphocytes no strict correlation between CD23 expression and STAT6 activation was detected in B-CLL. Therefore further signalling pathways and transcription factors in addition to STAT6 have to be activated to explain the high expression of CD23 in B-CLL cells. For example, STAT1 which is induced by IFN-gamma and binds to the classical STAT6 site. It might be involved in the strong induction of CD23 on B-CLL cells after cotreatment with IL-4 and IFN-gamma, while in non-malignant B lymphocytes IFN-gamma leads to a reduction of IL-4 mediated CD23 expression.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10713330     DOI: 10.1016/s0145-2126(99)00191-5

Source DB:  PubMed          Journal:  Leuk Res        ISSN: 0145-2126            Impact factor:   3.156


  5 in total

1.  A microfilament formation inhibitor, cytochalasin strongly enhances the low-affinity Fc epsilon receptor II (CD23) expression on the human monocyte-like cell line, U937.

Authors:  N Ikewaki; H Tamauchi; A Yamada; M Aoki; R Yamamoto; A Sawada; H Inoko
Journal:  J Clin Immunol       Date:  2000-11       Impact factor: 8.317

2.  Overexpression of IL-9 induced by STAT6 activation promotes the pathogenesis of chronic lymphocytic leukemia.

Authors:  Na Chen; Kang Lu; Peipei Li; Xiao Lv; Xin Wang
Journal:  Int J Clin Exp Pathol       Date:  2014-04-15

3.  Characterization of a variant of t(14;18) negative nodal diffuse follicular lymphoma with CD23 expression, 1p36/TNFRSF14 abnormalities, and STAT6 mutations.

Authors:  Imran N Siddiqi; Julia Friedman; Keegan Q Barry-Holson; Charles Ma; Venkata Thodima; Irene Kang; Raghavendra Padmanabhan; Lizalynn M Dias; Kevin R Kelly; Russell K Brynes; Sitharthan Kamalakaran; Jane Houldsworth
Journal:  Mod Pathol       Date:  2016-03-11       Impact factor: 8.209

4.  GIFT4 fusokine converts leukemic B cells into immune helper cells.

Authors:  Jiusheng Deng; Andrea Pennati; Jonathon B Cohen; Yuanqiang Wu; Spencer Ng; Jian Hui Wu; Christopher R Flowers; Jacques Galipeau
Journal:  J Transl Med       Date:  2016-04-27       Impact factor: 5.531

Review 5.  Recent Advances in the Inhibition of the IL-4 Cytokine Pathway for the Treatment of Allergen-Induced Asthma.

Authors:  Oliver Massey; Cenk Suphioglu
Journal:  Int J Mol Sci       Date:  2021-12-20       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.